首页> 外文期刊>The John Marshall journal of computer & information law >THE FOOD AND DRUG ADMINISTRATION AND THE FUTURE OF THE BRAIN-COMPUTER INTERFACE: ADAPTING FDA DEVICE LAW TO THE CHALLENGES OF HUMAN-MACHINE ENHANCEMENT
【24h】

THE FOOD AND DRUG ADMINISTRATION AND THE FUTURE OF THE BRAIN-COMPUTER INTERFACE: ADAPTING FDA DEVICE LAW TO THE CHALLENGES OF HUMAN-MACHINE ENHANCEMENT

机译:食品和药物的管理以及大脑与计算机之间的接口的未来:将FDA装置法适应人机增强的挑战

获取原文
获取原文并翻译 | 示例

摘要

Brain-computer interfaces in general, and neuroelectronic user devices in particular, are still in their infancy. Vast challenges remain in making these devices both commercially and technologically feasible. In particular, it remains to be seen whether neuroelectronic interfaces can overcome the current challenges of biocompatibility and long-term signal degradation, or whether other less invasive technologies such as EEGs and myoelectric interfaces can drastically increase in performance. Only time will tell if these technologies fulfill their potential, and only time will tell how and if they will impact our lives and our world. In the meantime, however, pre-emptive regulation by the FDA, the agency with the regulatory system most suited to handle these new devices, would be a prudent course of action. Encouragingly, most of the FDA's existing regulatory tools can be adapted for this task. Though legislative intervention might be needed to implement some of the details of the proposed Class IV and Class IV-E designations, many of the adjustments that would ensure safety and effectiveness, such as more rigorous enforcement of the FDA's postmarket authorities, as well as the Enhancement Panel approach, should be initiated by the agency alone. To summarize, a competent default regime, such as the one proposed here, would serve multiple functions. First, it would respond to the heightened, long-term safety & effectiveness risks presented by neuroelectronic devices in general, and user enhancement devices in particular. Second, it would help assure the public at large that something is being done about these new, challenging technologies. But perhaps more important than the damage control role that such a regime might play is the role in which a FDA regime would play in raising awareness about neuroelectronic user devices and guiding their development. It will have the ability to foster a substantive discussion of the problems associated with enhancement, while simultaneously allowing the underlying technologies time to develop.
机译:总体而言,脑机接口,尤其是神经电子用户设备仍处于起步阶段。使这些设备在商业和技术上都可行仍然面临着巨大的挑战。尤其是,神经电子接口是否可以克服当前生物相容性和长期信号降解的挑战,或者诸如EEG和肌电接口之类的其他侵入性较小的技术是否可以大幅提高性能,还有待观察。只有时间才能证明这些技术是否能够发挥其潜力,只有时间才能证明这些技术如何以及是否会影响我们的生活和我们的世界。但是,与此同时,FDA的先发制人监管是最谨慎的做法,而FDA是拥有最适合处理这些新设备的监管体系的机构。令人鼓舞的是,大多数FDA现有的监管工具都可以适应此任务。尽管可能需要采取立法干预措施来实施拟议的IV级和IV-E级名称的某些细节,但是许多可以确保安全性和有效性的调整,例如对FDA上市后当局的更严格执行以及增强小组方法应仅由代理商发起。总而言之,一种有效的默认制度(例如此处提出的默认制度)将发挥多种作用。首先,它将对通常由神经电子设备,尤其是用户增强设备带来的长期安全性和有效性风险做出反应。其次,这将有助于确保广大公众对这些具有挑战性的新技术有所作为。但是,与这种机制可能起到的损害控制作用相比,也许更重要的是FDA机制在提高对神经电子用户设备的认识并指导其发展方面所起的作用。它将有能力促进与增强相关的问题的实质性讨论,同时使基础技术有发展的时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号